By Fineline Cube 
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.
HB0043 Mechanism and Potential
HB0043 is designed with high binding and blocking activity, enabling it to effectively inhibit cytokine-induced inflammation and fibrosis. Preclinical studies in animal models of atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), diabetes nephropathy (DN), neutrophil asthma, and other diseases have demonstrated superior efficacy compared to single-target drugs.-Fineline Info & Tech